EPS for Nektar Therapeutics (NKTR) Expected At $0.21

October 8, 2017 - By Max Morgan

 EPS for Nektar Therapeutics (NKTR) Expected At $0.21
Investors sentiment increased to 1.89 in Q2 2017. Its up 0.72, from 1.17 in 2017Q1. It increased, as 17 investors sold Nektar Therapeutics shares while 40 reduced holdings. 25 funds opened positions while 83 raised stakes. 147.16 million shares or 3.57% more from 142.09 million shares in 2017Q1 were reported.
1492 Capital Mngmt Limited Liability Company holds 0.71% or 41,420 shares. Citadel Limited Liability Corp owns 127,201 shares. National Bank & Trust Of Montreal Can has 0% invested in Nektar Therapeutics (NASDAQ:NKTR). Wells Fargo & Mn stated it has 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Moreover, Legal & General Pcl has 0% invested in Nektar Therapeutics (NASDAQ:NKTR) for 295,003 shares. Rhenman And Prns Asset Management holds 2.23% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 795,000 shares. D E Shaw And stated it has 135,798 shares. Genesee Valley has invested 0.09% in Nektar Therapeutics (NASDAQ:NKTR). Parametric Port Ltd Llc reported 0.01% in Nektar Therapeutics (NASDAQ:NKTR). State Of New Jersey Common Pension Fund D reported 105,000 shares. Great West Life Assurance Company Can invested in 0.01% or 223,215 shares. Stoneridge Partners Limited Com accumulated 52,856 shares or 0.15% of the stock. Everence invested in 0.05% or 10,150 shares. The Texas-based Employees Retirement Sys Of Texas has invested 0.02% in Nektar Therapeutics (NASDAQ:NKTR). 184,200 are held by Utd Automobile Association.

Since April 7, 2017, it had 0 buys, and 9 insider sales for $2.51 million activity. 7,000 shares valued at $140,350 were sold by Lingnau Lutz on Friday, April 7. 3,146 shares valued at $61,504 were sold by Nicholson John on Tuesday, May 16. Doberstein Stephen K also sold $33,255 worth of Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, May 16. Labrucherie Gil M sold $62,149 worth of stock. $98,950 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by CHESS ROBERT on Monday, May 15. The insider Thomsen Jillian B. sold $51,827.

Investors wait Nektar Therapeutics (NASDAQ:NKTR) to report on November, 2. its quarterly earnings Wall Street analysts expect $0.21 EPS, up $0.53 or 165.63 % from last year’s $-0.32 same quarter earnings. This translates into $32.84 million profit for NKTR giving the stock a 29.54 P/E. This is assuming the current $0.21 EPS is accurate. Nektar Therapeutics’s Wall Street analysts see -153.85 % EPS growth, taking into account the $-0.39 EPS reproted in the previous quarter, The stock increased 0.49% or $0.12 on October 6, reaching $24.81. About 803,953 shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since October 8, 2016 and is uptrending. It has outperformed by 24.82% the S&P500.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 7 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 14 analyst reports since August 6, 2015 according to SRatingsIntel. Roth Capital maintained the stock with “Buy” rating in Tuesday, May 30 report. Aegis Capital maintained the shares of NKTR in report on Monday, June 5 with “Buy” rating. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Thursday, July 20. Roth Capital has “Buy” rating and $3100 target. The firm has “Overweight” rating by Piper Jaffray given on Thursday, January 7. Roth Capital maintained the stock with “Buy” rating in Monday, September 21 report. Roth Capital maintained the shares of NKTR in report on Wednesday, August 30 with “Buy” rating. The rating was downgraded by TheStreet on Wednesday, August 26 to “Hold”. The firm has “Buy” rating given on Tuesday, July 18 by J.P. Morgan. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Tuesday, November 8 by Aegis Capital. The firm earned “Buy” rating on Wednesday, August 16 by Jefferies.

Nektar Therapeutics is a biopharmaceutical firm that discovers and develops medicines in areas of high unmet medical need. The company has market cap of $3.88 billion. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It currently has negative earnings. It leverages its chemistry platform to discover and design new drug candidates.

More important recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Prnewswire.com which released: “Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of …” on September 12, 2017, also Prnewswire.com published article titled: “Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at …”, Seekingalpha.com published: “Nektar Therapeutics Building A More Exciting Pipeline” on September 26, 2017. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) was released by: Prnewswire.com and their article: “Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member” with publication date: September 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com